The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth
| Autor: | Ariane van der Straten, Shannon O'Rourke, Emily A Krogstad, Millicent Atujuna, Linda-Gail Bekker, Alexandra Minnis, Miriam Hartmann, Sheily Ndwayana, Elizabeth T. Montgomery |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Anti-HIV Agents Population HIV Infections Article Interviews as Topic South Africa Young Adult Pre-exposure prophylaxis medicine Humans Pharmacology (medical) Product (category theory) education education.field_of_study business.industry Patient Preference Focus group Preference Infectious Diseases Delayed-Action Preparations Family medicine New product development Sexual orientation Female Pre-Exposure Prophylaxis Psychology business Qualitative research |
| Zdroj: | JAIDS Journal of Acquired Immune Deficiency Syndromes. 80:542-550 |
| ISSN: | 1525-4135 |
| Popis: | BACKGROUND Long-acting injectable and implantable approaches aim to overcome some of the documented challenges with uptake and adherence to current HIV prevention methods. Youth are a key end-user population for these methods. We used qualitative methods to examine product attributes and preferences for current and future long-acting HIV prevention approaches. METHODS Ninety-five South African youth aged 18-24 years, of whom 62 were female and 33 male, completed 50 interviews and 6 focus groups. We purposively selected for previous product experience, including oral pre-exposure prophylaxis, injectable pre-exposure prophylaxis, or the vaginal ring, to ensure participants' opinions were rooted in actual experience. RESULTS Irrespective of previous method-use experience, gender, or sexual orientation, the majority expressed a preference for prevention methods formulated as injectables or implants. Several mentioned that their top priority in any product was efficacy, and for some, this overrode other concerns; for example, even if they feared pain, an implant or an injectable would be used if fully protective. Although efficacy was a top priority, there was also a clear desire across all subgroups for a product that would not interfere with sex, would stay in the system to provide protection, and that caused minimal burden, or was not apparent to others, and these characteristics were most salient for long-acting methods. CONCLUSIONS Narrative explanations for preferences converged thematically around different dimensions of "invisibility" including invisibility to oneself, one's partner and household members, and community members. End-user preferences can be used to inform product development of long-acting HIV prevention approaches formulated as injections or implants to optimize adherence and impact. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|